MECOM and acute myeloid leukemia: Although earlier studies demonstrated no significant survival difference between patients with <20% (previously classified as MDS) and ≥20% blasts—supporting the removal of the arbitrary blast cut-off—a recent study suggests that blast percentage retains prognostic significance within MECOM-rearranged AML [33,34,35].